Tags

ras inhibitor first in class — 1 pages

Closed FDA Approves Daraxonrasib (Rasonque) — First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer On Aug 26, 2026 the FDA approved Rasonque (daraxonrasib), Revolution Medicines' first-in-class RAS inhibitor for metastatic pancreatic cancer; trial survival was 13.2 vs 6.7 months. Science · Oct 8